

NEWSLETTER

Volume 12, June 2026

UPDATES IN BRIEF: JAN – JUNE 2026



ANNOUNCEMENTS

- We are pleased to announce the HCC 6th Annual Meeting, to be held on 9–10 October 2026 at Believers Church Medical College Hospital, Thiruvalla, Kerala.
- ‘Patterns of Care and Outcomes of Adults ≥ 40 Years with Newly Diagnosed ALL: A Multicenter Registry Analysis from India’ (PI: Dr. Punit Jain) has been accepted for publication in JCO Global Oncology.



CONGRATULATIONS

We extend our heartfelt congratulations to:

- Dr. Manju Sengar for receiving the prestigious International Women Who Conquer Cancer Mentorship Award from Conquer Cancer, the ASCO Foundation. [Read more ↗](#)
- Dr. Hasmukh Jain for receiving the Breakthrough Research Yvonne Award 2026. [Read more ↗](#)

MEMBERSHIP UPDATE

38

Institutional Partners

817

Individual members, Consultants, Physicians, Nurses, Data Entry Operators and Patients

OUR NEW INSTITUTIONAL PARTNERS

Baby Memorial Hospital
Kozhikode, Kerala

Cachar Cancer Hospital
& Research Centre
Silchar, Assam

Asian Institute of
Medical Sciences
Faridabad, Haryana

Individuals and institutions with an interest in hematological malignancies are welcome to join. Register at: <https://www.hemecancer.org/membership.php>

ACCOMPLISHMENTS SO FAR...

45,300

Patients Enrolled

38

Partner Centres

19

ASH Abstracts Selected

7

Studies Published

Studies	Completed	Ongoing
Observational	11	10
Interventional	1	5

ASH Abstracts: <https://www.hemecancer.org/abstracts.php>

PUBLICATIONS

Manuscripts Under Submission:

- Nationwide Survey of Azacitidine-Venetoclax Use in Indian Patients with AML: Variability in Practice and the Need for Standardization.
- Patterns of Care and Outcomes of Adults ≥ 40 Years with Newly Diagnosed ALL: A Multicenter Registry Analysis from India — Manuscript has been accepted by JCO-Global Oncology; Publication awaited.
- Evaluation of Safety and Efficacy of Generic Low-Dose Dasatinib for Frontline Therapy in Chronic-Phase CML — GLaD Study. Submission in process.

7 studies published to date. Full list: <https://www.hemecancer.org/publication.php>

HCC REGISTRY

The total patients enrolled in each registry till June 2026 is as mentioned below:

i. AML, ALL and APML: 2018 - June 2026

ii. Lymphoma and CML: 2020 - June 2026

iii. MDS and MPN: 2024 - June 2026

Registry	Centres	Total Patients Enrolled
AML Registry	37	10,759
ALL Registry	35	8,601
APML Registry	32	1,492
CML Registry	35	6,167
Lymphoma Registry	33	17,867
MDS Registry	19	183
MPN Registry	18	231
Total	209	45,300

RESEARCH AND WORKING GROUP UPDATES

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) WORKING GROUP

Ongoing Studies:

A multicentre Phase III randomized control trial to test the efficacy of targeted agents during induction and a response-adapted consolidation in adolescent and young adult patients with de-novo ALL. (TARGET Study)

- PI: Dr. Hasmukh Jain
- CTRI Registration No: CTRI/2025/03/082015
- Sample size: 1,080 patients (812 B-ALL + 268 T-ALL cohorts)
- Study duration: 3 years accrual + 36 months follow-up
- Update: Total 66 patients enrolled in the study. Funds are being raised through NCG

Pediatric inspired (BFM) protocol in adolescent and young adults (AYA) with ALL in India: Real-world treatment timelines and impact of delays on survival. (TIMELY Study)

- PI: Dr. Chepsy Philip
- Update: Abstract published at ASH 2025. Source data verification ongoing

A study to compare the outcomes with inotuzumab ozogamicin used as a bridge to allogeneic stem-cell transplant versus CAR T-cell therapy.

- PI: Dr. Uday Kulkarni
- Retrospective study from Jan 2020 till Dec 2024 with 7 centres
- Update: Source data verification ongoing for Abstract submission

ACUTE MYELOID LEUKEMIA (AML) WORKING GROUP

Ongoing Studies:

Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study. (HCC pRISM-S)

- PI: Dr. Smita Kayal
- CTRI Registration No: CTRI/2020/07/026450
- Update: 3-year follow-up data collection ongoing. Source data verification completed. Working on study close-out

COVID-19 with Hematological Cancers Registry of India. (CHCRI Study)

- PI: Dr. Arihant Jain
- Enrolment complete. 5-year follow-up data collection is ongoing. Initial data has been published in Blood Cancer Journal

Cont...

Comparative evaluation of consolidation strategies subsequent to azacitidine plus venetoclax-based induction in AML patients: A retrospective analysis of Haematological Cancer Consortium (HCC) registry in India.

- PI: Dr. Gaurav Prakash
- Retrospective study from Jan 2020 to Dec 2025 with 13 participating centres
- Update: Data analysis ongoing for Abstract submission

Stratifying using Clinical and Genomics data for Risk Evaluation in Less Intensive Therapy for Acute Myeloid Leukemia in the Elderly. (SCORE-LIT Study)

- PI: Dr. Chepsy Philip
- Update: Abstract published at ASH 2025. Source data verification ongoing

Phase III open labelled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of low and intermediate risk acute promyelocytic leukemia. (HCC-APL22 DOSA Study)

- PI: Dr. Vikram Mathews and Dr. Manju Sengar
- CTRI Registration No: CTRI/2023/09/057990
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 7 years
- This study is funded by NCG
- Update: Total 82 patients have been enrolled in the study; Enrollment ongoing

Treatment trends over time in the management of acute myeloid leukemia in adults between 18 to 60 years of age in India.

- PI: Dr. Uday Kulkarni
- Retrospective study from January 2018 to December 2025 with 21 participating centres
- Update: Data analysis ongoing for Abstract

MDS/MPN WORKING GROUP

Ongoing work:

- The MDS and MPN Registries are made live for capturing the data
- The group plans to develop prospective studies

LYMPHOMA WORKING GROUP

Ongoing Studies:

A phase III randomized study to compare a risk-stratified and response-adapted strategy to ABVD regimen in adolescents and adults with advanced-stage Hodgkin lymphoma. (ABVD Hodgkin's Study)

- PI: Dr. Hasmukh Jain
- CTRI Registration No: CTRI/2020/12/030132
- Sample size: 200 patients
- Study duration: 4 years accrual, 3 years follow-up since last enrolled patient and 10 years for long-term follow-up phase
- Update: Patient recruitment completed. Long-term follow-up of patients is ongoing

A Phase III Randomized Study of Low Dose Nivolumab Plus AVD or ABVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. (LoNAH Study)

- PI: Dr. Anu Korula
- CTRI Registration No: CTRI/2024/03/063942
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 3 years. This study is funded through a grant from ICMR
- Update: Total 172 patients enrolled in the study

Impact of Consolidation Radiotherapy in Bulky Diffuse Large B cell Lymphoma by PET based Response Assessment. (DLBCL Study)

- PI: Dr. Chandran K Nair
- Update: Source data verification completed; manuscript writing in process

HCC Lymphoma Core Group: Outcome of T-Cell Non-Hodgkin Lymphoma from HCC Registry. (T-NHL Study)

- PI: Dr. Sreeraj Vasudevan
- Update: Abstract published at ASH 2025. Source data verification ongoing

Role of Consolidative Radiotherapy in bulky and/or extra-nodal DLBCL with complete metabolic response after R-CHOP regimen: A Randomized Controlled Trial. (CORAD-DLBCL Study)

- PI: Dr. Sangeeta Kakoti
- Study duration: 4 years accrual + 2 years follow-up. Funded through Tata Memorial Centre Research Administration Council (TRAC)
- Update: A total of 50 patients have been enrolled in the study; enrollment is ongoing

CHRONIC MYELOID LEUKEMIA (CML) WORKING GROUP

Ongoing Studies:

To study outcomes in young CML treated with TKI in India (CML STOUT Study)

- PI: Dr. Kundan Mishra
- Manuscript preparation is ongoing and planned for submission

Evaluating Kidney Function in Long-Term Imatinib Therapy for CML Patients. (KITE Study)

- PI: Dr. Sanjeevan Sharma
- Update: Abstract published at ASH 2025. Source data verification ongoing

Indian Multicentric Pregnancy and Chronic Myeloid Leukemia Outcomes Tracking Study. (IMPACT-CML Study)

- PI: Dr. Suvir Singh
- Update: Abstract published at ASH 2025. Source data verification ongoing

Study Title: Long-term Outcomes of CML in Elderly Patients (Age $\geq$ 60 Years) in the Tyrosine Kinase Inhibitor Era: The eCML study

- PI: Col. Sanjeevan Sharma, Dr. Shouriy Ghosh
- Retrospective study from 1st January 2017 until 31st December 2024 with 18 participating centres
- Update: Data analysis ongoing for Abstract submission

EDUCATION & TRAINING

PATIENT ADVOCACY SESSION

- Patient advocacy group was launched in January 2023.
- These sessions take place on the third Saturday of every month at 11:00 AM, and the team has launched an online support group for patients, survivors and caregivers.
- Thirty-five support group sessions delivered till date.
- We are deeply grateful to all the experts for dedicating their time and conducting the sessions for patients and caregivers.

Support group meeting topics since January 2026:

Topic: Understanding Government and Non-Government Funding Sources for Supporting Treatments Speaker: Mr. Sanjeev Sharma Patient Advocate, Tata Memorial Hospital, Mumbai Date: 17 January 2026	
Topic: Living Well During and After Treatment — Conversation with an Oncologist, a Caregiver and a Survivor Speakers: Dr. Priyanka Samal, Mr. Mir Yawer, Mr. Nipun Sarin Moderator: Mr. Bhagwan Mishra Date: 21 February 2026	
Topic: Survivorship in Blood Cancer Speaker: Dr. Maya Prasad Professor, Pediatric Oncology, Tata Memorial Hospital, Mumbai Date: 21 March 2026	
Topic: The New Normal- Life After Cancer Treatment Speakers: Mr. Dar Tanveer, Ms. Priyanka Baranwal, Mr. Bhagwan Mishra Date: 18 April 2026	
Topic: Blood Cancer- Diagnosis and Treatment Speaker: Dr. Manju Sengar Professor, Medical Oncology, Tata Memorial Hospital, Mumbai Date: 16 May 2026	

EDUCATION & TRAINING

NURSING WEBINARS

- Nursing Education Program was launched in January 2021 to strengthen nurses' clinical knowledge and skills.
- Monthly webinars are conducted on the last Tuesday of every month at 3:00 PM.
- Fifty-four sessions delivered till date.
- Thank you Team! We are deeply grateful to all the experts for dedicating their time and conducting the sessions for nurses.

Nursing webinars conducted since January 2026:

Topic: Management of Relapsed ALL Speaker: Dr. Jasmeet Sidhu Consultant (Pediatric Hematology and Oncology), Medical Oncology, Homi Bhabha Cancer Hospital and Research Center, New Chandigarh Date: 27 January 2026	
Topic: Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Speakers: Maj. Helna KV & Maj. Pallawi Mane Army Hospital (R&R) Date: 24 February 2026	 
Topic: Extracorporeal Photopheresis (ECP) and the Nurse's Role Speaker: Capt. Uzma Bano Nursing Officer, Dept of Hematology, Army Hospital R&R Delhi Date: 31 March 2026	
Topic: Role of Alpha-Beta T-Cell Depletion in the Prevention of Graft-versus-Host Disease (GVHD) Speaker: Dr. Rasmi Palassery Associate Professor, Department of Medical Oncology, Ramaiah Medical College, Bengaluru Date: 28 April 2026	
Topic: Heart of Healthcare: Celebrating nurses Speakers: Mrs. Amala Lucas, Mr. Bharath Kumar S H, Ms. Amrita Gope, Ms. Monima Baruah, Ms. Sathyabala R, Ms. Surya Sukumaran, Ms. Simran Preet Kaur Date: 26 May 2026	
     	

DATA ENTRY OPERATOR TRAINING (DEO)

- We are assessing and identifying areas where DEOs need training and accordingly offering customized training sessions.
- Training recordings are available at: <https://www.hemecancer.org/training-module.php>

DEO Training Session conducted since January 2026:

Topic: ALL Registry Training

Speaker: Dr. Hasmukh Jain

Professor, Medical oncology, Tata Memorial Hospital, Mumbai

Date: 13 February 2026, 15 May 2026

Topic: MDS Registry training

Speakers: Dr. Joseph John, Mr. Rajkumar and Ms. Mandeep kaur

Date: 27 February 2026

Topic: MPN Registry training

Speaker: Dr. Chepsy Philip

Professor, Medical oncology, Believers Church Medical College Hospital, Thiruvalla, Kerala.

Date: 27 March 2026

Topic: Lymphoma Registry training

Speaker: Dr. Charanpreet Singh

Professor, Clinical Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh

Date: 12 June 2026

**HCC EXPRESSES HEARTFELT GRATITUDE TO THE
NATIONAL CANCER GRID (NCG) FOR ITS CONTINUED
SUPPORT OF THE HEMATOLOGICAL CANCER REGISTRY
AND COLLABORATIVE RESEARCH INITIATIVES.**



**WE THANK OUR INDIVIDUAL AND CORPORATE
SUPPORTERS FOR THEIR GENEROUS
CONTRIBUTIONS AND PARTNERSHIP IN
ADVANCING RESEARCH, EDUCATION, AND PATIENT
CARE.**



**HCC ALSO EXTENDS SINCERE APPRECIATION TO
OUR INSTITUTIONAL PARTNERS FOR THEIR DATA
CONTRIBUTIONS, RESEARCH PARTICIPATION, AND
COLLABORATION IN STRENGTHENING THE REGISTRY
AND DRIVING MULTICENTRE RESEARCH ACROSS
INDIA.**

**INDIVIDUALS AND INSTITUTIONS WITH AN INTEREST IN HEMATOLOGICAL MALIGNANCIES
CAN BECOME MEMBERS, REGISTER : [HTTPS://WWW.HEMECANCER.ORG/MEMBERSHIP.PHP](https://www.hemecancer.org/membership.php)**

